TIDMONC
RNS Number : 2466S
Oncimmune Holdings PLC
13 July 2022
13 July 2022
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces that options to subscribe
for ordinary shares of GBP0.01 each in the Company ("Ordinary
Shares") have been granted to Alistair Macdonald following his
appointment as the Company's Non-executive Chair on 8 July
2022.
Alistair Macdonald has been granted 127,389 options at an
exercise price of GBP0.785 per Ordinary Share and 492,252 options
(the "Scheme Options") at an exercise price of GBP0.01 per Ordinary
Share pursuant to the incentivisation scheme established for
members of senior management in September 2020 (the "Scheme"). The
Scheme Options will vest based on the performance of the Company's
share price over the course of the three years from the
establishment of the Scheme, between GBP2.00 and GBP3.50 ("Target
Share Price") (as set out below), which must be achieved for 20
consecutive business days or on certain trigger event. This vesting
mechanism is directly aligned with the delivery of shareholder
value. Once vested, Options (or resulting shares) must be held for
a further two years, subject to certain exceptions and acceleration
events. The Target Share Prices and associated vesting levels for
Alistair Macdonald's Scheme Options are as follows:
Target Share Price
GBP2.00 GBP2.50 GBP2.75 GBP3.00 GBP3.50
-------- -------- -------- --------
Percentage of Award Vesting
25% 50% 62.5% 75% 100%
-------- -------- -------- --------
Total Number of Options Vesting
123,063 246,126 307,658 369,189 492,252
-------- -------- -------- --------
The Scheme Options granted to Alistair Macdonald replace the
unvested options granted to former Chair Meinhard Schmidt in
September 2020, which have now lapsed following Meinhard's
retirement from the Board.
This announcement, including the notification below, is made in
accordance with the requirements of the UK Market Abuse Regulation
and serves as notification and public disclosure of transactions by
persons discharging managerial responsibilities ("PDMR") and
persons closely associated with them.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Alistair Macdonald
-------------------------------- --------------------------------------
Reason for the notification
2
------------------------------------------------------------------------
a) Position/status Non-executive Chair
-------------------------------- --------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
-------------------------------- --------------------------------------
b) LEI 213800HCYIWT6YPI1I02
-------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description Ordinary Shares of GBP0.01 each
of the financial
instrument,
type of instrument
Identification ISIN: GB00BYQ94H38
code
b) Nature of the 1) Grant of options
transaction 2) Grant of Scheme Options
-------------------------------- --------------------------------------
c) Price(s) and
volume(s)
------------------- --------------
Price(s) Volume(s)
------------------- --------------
1) GBP0.785 127,389
--------------------------------------------------------- --------------
2) GBP0.01 492,252
--------------------------------------------------------- --------------
d) Aggregated N/A - single transactions
information
- Aggregated
volume
- Price
e) Date of the 12 July 2022
transaction
-------------------------------- --------------------------------------
f) Place of the Outside a trading venue
transaction
-------------------------------- --------------------------------------
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Erland Sternby
+44 (0)20 3705 9321
Media enquiries:
John Goold
IR@oncimmune.com
About Oncimmune
ImmunoINSIGHTS Service Business
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. The ImmunoINSIGHTS service
business leverages Oncimmune's technology platform and
methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the
development and product lifecycle. Our core immune-profiling
technology is underpinned by our library of over eight thousand
immunogenic proteins, one of the largest of its kind. This helps
identify trial participants and patients into clinically relevant
subgroups, enabling development of targeted and more effective
treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the
Company's discovery research centre in Dortmund, Germany. The
business platform enables life science organizations to optimize
drug development and delivery, leading to more effectively targeted
and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and
Europe and Oncimmune is seeking to replicate the Dortmund facility
in the US in the medium term.
EarlyCDT Product Business
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect
and help identify cancer on average four years earlier than
standard clinical diagnosis. Our lead diagnostic test, EarlyCDT
Lung, targets a vast market estimated to grow to GBP3.8bn by 2024.
With over 200,000 tests already performed for patients worldwide
and its use being supported by peer reviewed data in over 12,000
patients, we are poised to become an integral component of future
lung cancer detection programs, globally.
Oncimmune's diagnostic products business is located at its
laboratory facility in Nottingham, UK.
For more information, visit www.oncimmune.com
What is SeroTag(TM) ?
Oncimmune's proprietary biomarker discovery engine, which is
leveraged in our ImmunoINSIGHTS services to discover and validate
novel biomarkers can help stratify patients in multiple cancer
indications and with different autoimmune diseases.
This high-throughput, multiplex technology is based on one of
the largest, in-house protein libraries, as well as a unique,
ever-growing repository of disease data for indications including,
but not limited to, autoimmune diseases and cancer. As a result,
SeroTag is helping to address and monitor a number of challenges
currently hindering the successful development and broader
application of both cancer immunotherapies and treatments for
autoimmune diseases.
The platform is being applied to discover and validate
biomarkers and develop precision diagnostic tools from minimally
invasive liquid biopsies. SeroTag analyses autoantibodies-some of
the most stable analytes-and is used most frequently for the
identification of IgG isoforms, in addition to IgM and IgA, from
just a few drops of serum.
The SeroTag platform acts as the primary discovery engine that
feeds into the creation of Oncimmune's NavigAID(TM)
disease-specific stratification panels. These precision medicine
tools which are enabling patient and disease stratification and
support therapeutic development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBKBBBFBKDDOD
(END) Dow Jones Newswires
July 13, 2022 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024